Literature DB >> 1523975

Spinal cord vascular and leptomeningeal amyloid beta-protein deposition in a case with cerebral amyloid angiopathy.

T Tokuda1, S Ikeda, K Maruyama, N Yanagisawa, N Ito.   

Abstract

Cerebral amyloid angiopathy (CAA) is characterized by the deposition of amyloid fibrils on leptomeningeal and cortical blood vessels, and the incidence of this disorder increases with age. However, this form of vascular amyloid deposition rarely involves tissues outside of the brain. A 71-year-old woman first developed some deterioration in memory, and soon afterwards suffered from recurrent episodes of subcortical hemorrhage. Histopathological examination of this case revealed typical pathology of Alzheimer's disease with an extensive appearance of beta-protein type CAA, and additionally, the spinal leptomeningeal vessels and the pia-arachnoid membranes were also affected by amyloid beta-protein deposits. The spinal cord involvement associated with CAA and Alzheimer's disease is unusual, and the present case provides additional important information on the pathogenesis of disorders with beta-protein deposition including Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1523975     DOI: 10.1007/bf00311397

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  26 in total

1.  Early senile plaques in Alzheimer's disease demonstrated by histochemistry, immunocytochemistry, and electron microscopy.

Authors:  S Ikeda; N Yanagisawa; D Allsop; G G Glenner
Journal:  Hum Pathol       Date:  1990-12       Impact factor: 3.466

2.  Re-examination of ex-boxers' brains using immunohistochemistry with antibodies to amyloid beta-protein and tau protein.

Authors:  T Tokuda; S Ikeda; N Yanagisawa; Y Ihara; G G Glenner
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

3.  Coexistence of Alzheimer's amyloid precursor protein and amyloid protein in cerebral vessel walls.

Authors:  F Tagliavini; J Ghiso; W F Timmers; G Giaccone; O Bugiani; B Frangione
Journal:  Lab Invest       Date:  1990-06       Impact factor: 5.662

Review 4.  Human amyloidosis, Alzheimer disease and related disorders.

Authors:  E M Castaño; B Frangione
Journal:  Lab Invest       Date:  1988-02       Impact factor: 5.662

5.  Novel precursor of Alzheimer's disease amyloid protein shows protease inhibitory activity.

Authors:  N Kitaguchi; Y Takahashi; Y Tokushima; S Shiojiri; H Ito
Journal:  Nature       Date:  1988-02-11       Impact factor: 49.962

6.  Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein.

Authors:  G G Glenner; C W Wong
Journal:  Biochem Biophys Res Commun       Date:  1984-05-16       Impact factor: 3.575

7.  The amyloid deposits in Alzheimer's disease: their nature and pathogenesis.

Authors:  G G Glenner; C W Wong; V Quaranta; E D Eanes
Journal:  Appl Pathol       Date:  1984

8.  Amyloid plaque core protein in Alzheimer disease and Down syndrome.

Authors:  C L Masters; G Simms; N A Weinman; G Multhaup; B L McDonald; K Beyreuther
Journal:  Proc Natl Acad Sci U S A       Date:  1985-06       Impact factor: 11.205

9.  beta-amyloid protein of Alzheimer's disease is found in cerebral and spinal cord vascular malformations.

Authors:  M N Hart; P Merz; J Bennett-Gray; A H Menezes; J A Goeken; R L Schelper; H M Wisniewski
Journal:  Am J Pathol       Date:  1988-07       Impact factor: 4.307

10.  Immunohistochemical characterization of the amyloid deposits and quantitation of pertinent cerebrospinal fluid proteins in hereditary cerebral hemorrhage with amyloidosis.

Authors:  H Löfberg; A O Grubb; E K Nilsson; O Jensson; G Gudmundsson; H Blöndal; A Arnason; L Thorsteinsson
Journal:  Stroke       Date:  1987 Mar-Apr       Impact factor: 7.914

View more
  1 in total

1.  Can brain impermeable BACE1 inhibitors serve as anti-CAA medicine?

Authors:  Jian-Ming Li; Li-Ling Huang; Fei Liu; Bei-Sha Tang; Xiao-Xin Yan
Journal:  BMC Neurol       Date:  2017-08-25       Impact factor: 2.474

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.